-transparent.png){kind=logo}
Treatment of rat glomerular mesangial cells with recombinant human interleukin 1 alpha (rIL-1 alpha), recombinant human interleukin 1 beta (rIL-1 beta) or recombinant human tumor necrosis factor (rTNF) induces prostaglandin E2 (PGE2) synthesis and the release of a phospholipase A2 (PLA2) activity. rIL-1 beta is significantly more potent than rIL-1 alpha or rTNF in stimulating PGE2 as well as PLA2 release from mesangial cells. When given together, rTNF interacts in a synergistic fashion with rIL-1 alpha and rIL-1 beta to enhance both, PGE2 synthesis and PLA2 release. The released PLA2 has a neutral pH optimum and is calcium-dependent. Pretreatment of cells with actinomycin D or cycloheximide inhibits basal and cytokine-stimulated PGE2 and PLA2 release.
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
November 1991,
The American journal of physiology,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
January 1991,
Biochemical and biophysical research communications,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
October 1990,
FEBS letters,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
September 1990,
Neuroscience letters,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
June 1990,
Biochemical and biophysical research communications,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
July 1990,
American journal of respiratory cell and molecular biology,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
May 1988,
FEBS letters,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
February 1994,
The Journal of biological chemistry,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
October 1997,
Biochimica et biophysica acta,
J Pfeilschifter, and
W Pignat, and
K Vosbeck, and
F Märki
November 1998,
Arthritis and rheumatism,
